Real‐world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single‐centre, prospective, open‐label study-Reference-Cited by-同舟云学术

Real‐world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single‐centre, prospective, open‐label study

Published:2022-04 Issue:7 Volume:36 Page:1064-1073
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Gu C.¹,Wu Y.¹^ORCID,Luo Y.²,Wang S.¹,Yin H.¹,Gao Y.²,Wang C.³,Yao X.²,Li W.¹^ORCID

Affiliation:

1. Department of Dermatology Huashan Hospital Fudan University Shanghai China

2. Department of Allergy and Rheumatology Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs Hospital for Skin Diseases Institute of Dermatology Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing China

3. Department of Biostatistics School of Public Health and The Key Laboratory of Public Health Safety of Ministry of Education Fudan University Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18109

Reference31 articles.

1. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

2. Epidemiology of atopic dermatitis in adults: Results from an international survey

3. Public Health Burden and Epidemiology of Atopic Dermatitis